Ignite Creation Date:
2024-05-05 @ 7:02 PM
Last Modification Date:
2024-10-26 @ 9:41 AM
Study NCT ID:
NCT00594594
Status:
TERMINATED
Last Update Posted:
2009-07-07
First Post:
2008-01-04
Brief Title:
Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury
Sponsor:
Lawson Health Research Institute
Organization:
Lawson Health Research Institute
Study Overview
Official Title:
A Multi-Centered Randomized Double-Blind Placebo-Controlled Trial for Efficacy in the Use of Adjuntive Probiotic Therapy in Reducing Urinary Tract Infections in Those Individual With Spinal Cord Injury
Status:
TERMINATED
Status Verified Date:
2009-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Unable to recruit enough patients to continue on with the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We hypothesize that probiotic Lactobacillus can augment antibiotic treatment of symptomatic urinary tract infection UTI in spinal cord injured patients and also increase the time to the next episode of UTI
Detailed Description:
Subjects will be recruited from the outpatient population and alumni of the Regional SCI Rehabilitation Programs in London Parkwood HospitalSt Josephs Health Care and Hamilton Hamilton Health Sciences Centre Ontario
Community living paraplegic and tetraplegic men and women 18 years and above who present to their family physician or specialist with symptomatic UTI will be prescribed an antibiotic treatment for up to 14 days using the drug of choice ie which the treating physician deems appropriate and randomized to also receive by mouth two capsules containing placebo or probiotic Lactobacillus rhamnosus GR-1 and L reuteri RC-14 daily
Community living paraplegic and tetraplegic men and women 18 years and above who present to their family physician or specialist with symptomatic UTI will be prescribed an antibiotic treatment for up to 14 days using the drug of choice ie which the treating physician deems appropriate and randomized to also receive by mouth two capsules containing placebo or probiotic Lactobacillus rhamnosus GR-1 and L reuteri RC-14 daily
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| HSREB 12845 | None | None | None |